Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T19:32:21.942Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of big data in psychiatry – the role of pharmacy registries

Published online by Cambridge University Press:  13 August 2021

M. Gonçalves-Pinho ,
J.P. Ribeiro ,
A. Freitas  and
P. Mota
M. Gonçalves-Pinho*
Affiliation:
Department Of Psychiatry And Mental Health, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal, Penafiel, Portugal
J.P. Ribeiro
Affiliation:
Department Of Psychiatry And Mental Health, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal, Penafiel, Portugal
A. Freitas
Affiliation:
2d4h, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal
P. Mota
Affiliation:
Departamento De Psiquiatria E Saúde Mental, Centro Hospitalar do Tâmega e Sousa, Guilhufe, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Administrative databases (AD) are repositories of administrative and clinical data related to patient contact episodes with all sorts of health facilities (primary care, hospitals, pharmacies,…).The large number of patients/contact episodes with pharmaceutical facilities available, the systematic and broad register and the fact that AD provides Real-world data are some of the pros in using AD data.

Objectives

To perform a narrative review on the role of Big Data pharmaceutical registries in Mental Health research.

Methods

We conducted a narrative review using MEDLINE and Google Scholar databases in order to analyse current literature regarding the role of BigData pharmaceutical registries in Mental Health Research.

Results

Administrative variables like drug names and prices may be used and linked to other clinical variables such as patients disease, in-hospital mortality, length of stay,(…). The use of electronic medical records may also contribute to systematic surveillance approaches like local or national pharmacovigilance strategies, identification of patients at risk of developing complications and software pop-up warnings related to medication dosage, duplication and lateral effects. The use of Big Data pharmaceutical registries allows to create predictive epidemiological models regarding drugs lateral effects or interactions and may help to perform pharmacovigilance phase 4 clinical trials. Its use may be applied to the optimization of clinical decision, monitoring of drug adverse events, drug cost and administrative monitoring and as surrogate measures of quality care indicators.

Conclusions

Big Data use in pharmaceutical registries allows to collect large and important clinical and administrative data that may be later used in Mental Health care and research.

Disclosure

No significant relationships.

Keywords

Big DataPsychiatryPharmacyDatabase
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S793
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.